Article

2016 Prostate Cancer Conference

Author(s):

PCRI

"The Prostate Cancer Research Institute, (PCRI), a 501(c)(3) not-for-profit organization, mission is to improve the quality of prostate cancer patients and caregivers lives by supporting research and disseminating information that educates and empowers patients, families and the medical community."

The Prostate Cancer Research Institute, (PCRI), a 501(c)(3) not-for-profit organization, mission is to improve the quality of prostate cancer patients and caregivers lives by supporting research and disseminating information that educates and empowers patients, families and the medical community.

This September 9-11, 2016, interact with practicing physicians and leading researchers to get your prostate cancer questions answered in multiple Q+A and breakout sessions! Topics cover everything from treatment options to side effect management. You will also glean from the experiences of your fellow patients and caregivers in support groups, dinners, and excursions. You will find empowering information that is relative to your case. We look forward to seeing you in September!

The Prostate Cancer Research Institute, (PCRI), a 501(c)(3) not-for-profit organization, mission is to improve the quality of prostate cancer patients and caregivers lives by supporting research and disseminating information that educates and empowers patients, families and the medical community.

The Prostate Cancer Research Institute, (PCRI), a 501(c)(3) not-for-profit organization, mission is to improve the quality of prostate cancer patients and caregivers lives by supporting research and disseminating information that educates and empowers patients, families and the medical community.

Learn more here >>

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Image of man with black hair.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of man with brown and grey hair.
Dr. Kelly Stratton
Related Content
The first patient has been enrolled in the ARID II trial for prostate cancer: stock.adobe.com.
April 24th 2025

First Patient Enrolled in ARID II Trial for Prostate Cancer Treatment

Spencer Feldman
The first patient has been enrolled in the ARID II trial evaluating Voro Urologic Scaffold to improve continence after prostate cancer surgery.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Image of man.
April 15th 2025

Nubeqa Combo Improves Outcomes in Metastatic Prostate Cancer

Kristi Rosa
Nubeqa plus hormone therapy improved outcomes in metastatic prostate cancer, reducing disease progression and showing a favorable safety profile.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Photo of a doctor and patient speaking over a desk
April 9th 2025

PROSTOX May Predict Urinary Side Effects Post Prostate Cancer Radiation

Alex Biese
A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study.
FDA sign.
April 1st 2025

Dive Into March 2025 FDA Approvals Across Cancer Subtypes

Ryan Scott
Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal cancers.